ICE Bioscience is a pioneering CRO+ Explorer company focusing on early drug discovery services, covering target validation to pre-clinical candidate identification. The company specializes in Immunology and Oncology, Cardiovascular, and CNS disease areas, utilizing robust capabilities and cutting-edge technologies. ICE Bioscience prioritizes professional communication and flexible collaboration models to expedite the drug discovery process.
ICE Bioscience prides itself on a comprehensive target-based panel screening platform and consistently broadens its repertoire of biological and pharmacological techniques to support diverse drug discovery objectives across various indications and clinical needs. With a wealth of experience and a fervor for developing new assays, the company concentrates on target identification, assay validation, and compound screening to progress from hit to lead and ultimately select pre-clinical drug candidates.
Founded in 2010, ICE Bioscience operates in the Biotechnology and Health Care industries. The company secured a Series B investment on 14 May 2024, with funding from Alwin Capital and Beijing E-town International Investment & Development.
